When gastrointestinal stromal tumour (GIST), the most common form of sarcoma, was first
recognized as a distinct pathological entity in the 1990s, patients with advanced-stage …

Gastrointestinal stromal tumours (GISTs) are a paradigm for the development of
personalized treatment for cancer patients. The nearly simultaneous discovery of a …

Background Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal
tumors of the gastrointestinal tract. Neoplastic GIST cells seem to arise from a common …

Accurate risk stratification of gastrointestinal stromal tumors (GISTs) has become
increasingly important owing to emerging adjuvant systemic treatments. All GISTs have …

Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumor of the
gastrointestinal (GI) tract. Soon after GIST was recognized as a tumor driven by a KIT or …

Gastrointestinal stromal tumors (GISTs) are potentially malignancies that can occur
anywhere in the digestive tract. Tyrosine kinase inhibitors (TKIs) such as imatinib have …

Abstract c-kit is a classical proto-oncogene that encodes a receptor tyrosine kinase (RTK)
that responds to stem cell factor (SCF). C-KIT signaling is a critical regulator of cell …

Gastrointestinal stromal tumours (GISTs) are the most common mesenchymal neoplasms of
the gastrointestinal tract. Despite clinicopathological differences, GISTs share oncogenic KIT …

Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the GI
tract, arising from the interstitial cells of Cajal, primarily in the stomach and small intestine …

Purpose Mutated KIT and platelet-derived growth factor alpha gene (PDGFRA) drive GI
stromal tumor (GIST) oncogenesis, but the clinical significance of their single mutations is …